Skip to main content
Premium Trial:

Request an Annual Quote

Predictive Biosciences Acquires OncoDiagnostic Laboratory

NEW YORK (GenomeWeb News) – Predictive Biosciences said today that it has acquired Cleveland, Ohio-based OncoDiagnostic Laboratory for an undisclosed sum.

OncoDiagnostic Laboratory is a Clinical Laboratory Improvement Act-certified anatomic pathology and molecular diagnostics lab serving urologists, gastroenterologists, dermatologists, gynecologists, and other subspecialty physicians nationwide.

Predictive, based in Lexington, Mass., said that the acquisition provides it with a fully integrated pathology laboratory through which it will commercialize its proprietary non-invasive molecular cancer diagnostic assays. The first of these assays is a urine-biomarker based test for the detection of bladder cancer, which Predictive plans to make commercially available sometime this year.

"ODL’s subspecialty expertise and national access to hundreds of urology practices including some of the largest group practices in the US, such as the Conrad|Pearson Clinic in Tennessee and the Arizona Urology Specialists, favorably position Predictive for launching our bladder cancer test as well as future diagnostic products," Predictive President and CEO Peter Klemm said in a statement.

ODL currently employs some 40 people, including a national sales force, and will continue to operate from its Cleveland headquarters, Predictive said.